Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2701 to 2750 of 8238 results

  1. Coronary revascularisation: Cangrelor (ESNM63)

    Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making

  2. Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

    Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

  3. Infantile haemangioma: topical timolol (ESUOM47)

    Summary of the evidence on topical timolol for treating infantile haemangioma (strawberry marks) to inform local NHS planning and decision-making

  4. Skin involvement in systemic sclerosis: rituximab (ES7)

    Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making

  5. Desflurane for maintenance of anaesthesia (ES41)

    Summary of the evidence on desflurane for maintenance of anaesthesia

  6. Antimicrobial prescribing: eravacycline for complicated intra-abdominal infections in adults (ES40)

    Summary of the evidence on eravacycline for complicated intra-abdominal infections in adults

  7. Antimicrobial prescribing: oritavancin for acute bacterial skin and skin structure infections (ES39)

    Summary of the evidence on oritavancin for acute bacterial skin and skin structure infections (ABSSSI) in adults

  8. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  9. Digital ulcers: sildenafil (ESUOM42)

    Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making

  10. Minimal change disease and focal segmental glomerulosclerosis in adults: rituximab (ES1)

    Summary of the evidence on rituximab for minimal change disease and focal segmental glomerulosclerosis to inform local NHS planning and decision-making

  11. Postural hypotension in adults: fludrocortisone (ESUOM20)

    Summary of the evidence on fludrocortisone for treating postural hypotension in adults to inform local NHS planning and decision-making

  12. Schizophrenia: omega-3 fatty acid medicines (ESUOM19)

    Summary of the evidence on omega-3 fatty acid medicines for treating schizophrenia to inform local NHS planning and decision-making

  13. Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)

    Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..

  14. Mitochondrial disorders in children: Co-enzyme Q10 (ES11)

    Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making

  15. Migraine prophylaxis: flunarizine (ESUOM33)

    Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making

  16. Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)

    Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making

  17. Chronic wounds: advanced wound dressings and antimicrobial dressings (ESMPB2)

    Summary of the evidence on advanced wound dressings and antimicrobial dressings for managing chronic wounds to inform local NHS planning and decision-making

  18. Hyperhidrosis: oral glycopyrronium bromide (ESUOM16)

    Summary of the evidence on oral glycopyrronium bromide for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  19. Cancer: breast cancer mortality rate (IND4)

    This indicator covers breast cancer mortality rates (female). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG04

  20. Cancer: breast screening (53 to 70 years) (IND65)

    This indicator covers the proportion of women aged 53 to 70 years whose record shows a breast screening test has been performed within the last 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG84

  21. Kidney conditions: CKD urine albumin:creatinine ratio (IND144)

    This indicator covers the percentage of patients on the CKD register whose notes have a record of a urine albumin:creatinine ratio (or protein:creatinine ratio) test in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM109

  22. Screening: cervical screening (50 to 64 years) (IND177)

    This indicator covers the proportion of patients eligible for cervical screening and aged 50 to 64 years at end of period reported whose notes record that an adequate cervical screening test has been performed in the previous 5.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM155

  23. Screening: cervical screening (25 to 49 years) (IND176)

    This indicator covers the proportion of patients eligible for cervical screening and aged 25 to 49 years at end of period reported whose notes record that an adequate cervical screening test has been performed in the previous 3.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM154

  24. Pregnancy and neonates: hip screening (IND77)

    This indicator covers the proportion of babies with a screen positive newborn hip result who attend for ultrasound scan of the hips within the designated timescale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG96

  25. Cancer: detected at stage 1 or 2 (all cancer) (IND3)

    This indicator covers the proportion of cancer cases detected at stage 1 or 2. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes

  26. Cancer: faecal immunochemical testing (IND267)

    This indicator covers the percentage of urgent suspected colorectal cancer referrals accompanied by a faecal immunochemical test (FIT) result, with the result recorded in the 21 days leading up to the referral. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM251.

  27. Learning disabilities: health checks, action plans and ethnicity (IND266)

    This indicator covers the percentage of patients on the learning disability register, who: received a learning disability health check and had a completed health action plan in the preceding 12 months and, have a recording of ethnicity. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM250

  28. Learning disabilities: health checks and action plans (IND265)

    This indicator covers the percentage of patients on the learning disability register who received a learning disability health check and had a completed health action plan in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM249

  29. Cancer: bowel screening (60 to 74 years) (IND64)

    This indicator covers the proportion of eligible people aged 60 to 74 years whose record shows a bowel screening test has been performed within the last 2.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG83

  30. Gynaecological conditions: rates of endometrial ablation (heavy menstrual bleeding) (IND59)

    This indicator covers rates of endometrial ablation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG78

  31. Gynaecological conditions: rates of hysterectomy (heavy menstrual bleeding) (IND58)

    This indicator covers rates of hysterectomy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG77

  32. Cancer: lung cancer stage at diagnosis (IND5)

    This indicator covers the proportion of lung cancer cases for which a stage at diagnosis is recorded. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG06

  33. Dementia: anti-psychotic prescriptions (IND12)

    This indicator covers the proportion of people with dementia prescribed anti-psychotic medication. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG18

  34. Cancer: invasive cancer diagnosed via emergency routes (IND1)

    This indicator covers the proportion of invasive cases of cancer diagnosed via an emergency route. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCC01

  35. Epilepsy: seizure free in preceding 12 months (IND145)

    This indicator covers the percentage of patients aged 18 or over on drug treatment for epilepsy who have been seizure free for the last 12 months recorded in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM110

  36. Dementia: care planning (IND142)

    This indicator covers the percentage of patients diagnosed with dementia whose care plan has been reviewed in a face-to-face review in the preceding 12 months. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM107

  37. Kidney conditions: CKD and renin–angiotensin system antagonists (IND130)

    This indicator covers the percentage of patients on the chronic kidney disease (CKD) register who have hypertension and proteinuria and who are currently being treated with an angiotensin-receptor blocker or an angiotensin-converting enzyme inhibitor. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM84

  38. Kidney conditions: CKD register (3a to 5) (IND129)

    This indicator ensures the contractor establishes and maintains a register of patients aged 18 years or over with chronic kidney disease (CKD) with classification of categories G3a to G5 (previously stage 3 to 5). It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM83

  39. Kidney conditions: AKI register (IND174)

    This indicator covers establishing and maintaining a register of all patients who have had an episode of AKI. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM152

  40. Epilepsy: register (IND253)

    This indicator covers the contractor establishing and maintaining a register of patients aged 18 or over receiving drug treatment for epilepsy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM237

  41. Dementia: register (IND252)

    This indicator covers the contractor establishing and maintaining a register of patients diagnosed with dementia. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM236

  42. Cancer: register (IND250)

    This indicator covers the contractor establishing and maintaining a register of all cancer patients excluding non-melanotic skin cancers. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM234

  43. Kidney conditions: CKD and blood pressure when ACR less than 70 (IND235)

    This indicator covers the percentage of patients on the CKD register and with an albumin to creatinine ratio (ACR) of less than 70 mg/mmol, without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if monitored in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM217

  44. Kidney conditions: CKD – eGFR and ACR (IND234)

    This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a-G5 (on the register, within the preceding 12 months) who had eGFR and ACR (urine albumin to creatinine ratio) measurements recorded within 90 days before or after diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM216

  45. Kidney conditions: CKD and eGFR (IND233)

    This indicator covers the percentage of patients with a new diagnosis of CKD stage G3a–G5 (on the register, within the preceding 12 months) who had eGFR measured on at least 2 occasions separated by at least 90 days, and the second test within 90 days before the diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM215.

  46. Cancer: review within 12 months (IND223)

    This indicator covers the percentage of patients with cancer, diagnosed within the preceding 24 months, who have a patient Cancer Care Review using a structured template within 12 months of diagnosis. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM205

  47. Cancer: review within 3 months (IND222)

    This indicator covers the percentage of patients with cancer, diagnosed within the preceding 12 months, who have had a discussion within 3 months of diagnosis about the support available from primary care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM204

  48. Multiple long-term conditions: medication review (IND207)

    This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186

  49. Multiple long-term conditions: frailty register (IND206)

    This indicator covers the practice can produce a register of people with moderate to severe frailty. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM185

  50. Multiple long-term conditions: multimorbidity register (IND205)

    This indicator covers the practice can produce a register of people with multimorbidity who would benefit from a tailored approach to care. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM184